title: Platelet-activating factor production during hemodialysis: effect of BN 52021.
abstract: Platelet activating factor (PAF) production and platelet-lipoxygenase activity were studied during hemodialysis (HD) with cuprophane membranes. Six patients were treated with first-use dialyzers (FU), and 6 patients with reused dialyzers (RU). In a random and double-blind design, 2 HD were performed for each patient, with or without BN 52021 pretreatment, a selective PAF antagonist. Platelet and leukocyte counts were performed before pretreatment and 30 min before HD starting (T-30), at the beginning of HD (T0) and after 15 and 30 min of HD (T15, T30). PAF production was analyzed by direct phase HPLC. To determine platelet-lipoxygenase activity, 12-HETE was detected by reverse phase high performance liquid chromatography (HPLC) after blood stimulation by the ionophore A23187. In the FU group, PAF and 12-HETE were produced during the first 30 min of HD. After BN 52021 pretreatment, PAF production was suppressed and platelet-lipoxygenase activity reduced. In the RU group, neither PAF nor 12-HETE production occurred, and BN 52021 had no effect. We conclude that PAF, which was involved in both platelet and leukocyte activation that occurred during hemodialysis, can be considered as a bio-incompatibility marker.
authors.affiliation: Department of Nephrology, Hospital Lapeyronie, Montpellier, France.
authors.forename: J P
authors.initials: JP
authors.lastname: Cristol
authors.forename: B
authors.initials: B
authors.lastname: Canaud
authors.forename: M
authors.initials: M
authors.lastname: Damon
authors.forename: C
authors.initials: C
authors.lastname: Chavis
authors.forename: B
authors.initials: B
authors.lastname: Arnoux
authors.forename: C
authors.initials: C
authors.lastname: Mion
mesh_terms: D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; D000686:Amyloidosis / Q000209:etiology; D001672:Biocompatible Materials; D001792:Blood Platelets / Q000201:enzymology; D000001:Calcimycin / Q000494:pharmacology; D002482:Cellulose / Q000009:adverse effects / Q000031:analogs & derivatives*; D004224:Diterpenes; D004311:Double-Blind Method; D005260:Female; D046934:Ginkgolides; D006801:Humans; D006893:Hydroxyeicosatetraenoic Acids / Q000096:biosynthesis / Q000097:blood; D007783:Lactones / Q000494:pharmacology*; D007970:Leukopenia / Q000209:etiology; D008084:Lipoxygenase / Q000378:metabolism; D008213:Lymphocyte Activation; D008297:Male; D008567:Membranes, Artificial; D008875:Middle Aged; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D015539:Platelet Activation; D011897:Random Allocation; D006435:Renal Dialysis / Q000009:adverse effects / Q000295:instrumentation*; D001613:beta 2-Microglobulin / Q000378:metabolism
chemical_list: D001672:Biocompatible Materials; D004224:Diterpenes; D046934:Ginkgolides; D006893:Hydroxyeicosatetraenoic Acids; D007783:Lactones; D008567:Membranes, Artificial; D010972:Platelet Activating Factor; D001613:beta 2-Microglobulin; D000001:Calcimycin; D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; D002482:Cellulose; C009865:cuprammonium cellulose; C045856:ginkgolide B; D008084:Lipoxygenase